Molecular Templates, Inc. (MTEM)
OTC PINK OTC PINK Primary Summary
Molecular Templates, Inc. (MTEM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Molecular Templates, Inc. ever had a stock split?
Molecular Templates, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric E. Poma CEO | OTC PINK Exchange | 608550208 CUSIP |
| US Country | 62 Employees | - Last Dividend | 20 Aug 2008 Last Split | 4 Feb 2005 IPO Date |
Overview
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company committed to the mission of discovering and developing novel therapeutics for the treatment of cancer and other significant diseases. Leveraging its proprietary biologic drug platform technology, Engineered Toxin Bodies (ETB), the company is pioneering the development of innovative biologic treatments. Founded in 2001, Molecular Templates has concentrated its research and development efforts to bring about meaningful advancements in medicine, with a strong focus on oncology. The company's headquarters are situated in Austin, Texas, placing it at the heart of one of America's burgeoning life sciences hubs. In its journey toward developing effective cancer therapies, Molecular Templates has entered into a strategic collaboration agreement with Bristol Myers Squibb, underscoring its potential and dedication to creating breakthrough treatments.
Products and Services
The development pipeline of Molecular Templates, Inc. is characterized by its innovative approach to cancer care, harnessing the power of its ETB platform to design unique therapies. Significant products in their lineup include:
- MT-8421: Currently in Phase I clinical trial, MT-8421 is a distinctive ETB candidate geared toward disrupting the Tumor MicroEnvironment (TME) by directly eliminating tumor and immune cells. This innovative approach aims at transforming cancer treatment by targeting the underlying mechanisms of tumor growth and immune evasion.
- MT-0169: This product is in Phase I clinical trial for patients with relapsed/refractory multiple myeloma. MT-0169 signifies Molecular Templates’ efforts in addressing some of the most challenging aspects of cancer therapy, focusing on a disease known for its complexity and difficulty to treat after relapse or resistance to first-line treatments.
- MT-6402: Aimed at patients with relapsed/refractory PD-L1 expressing tumors, MT-6402 is another testament to the versatility of the ETB platform. Also in Phase I clinical trials, this product emphasizes the company’s commitment to exploring novel avenues for the treatment of cancer, particularly in patients who have exhausted other therapeutic options.
